About I'Rom Group
I'Rom Group is a publicly listed company based in Tokyo (Japan) founded in 1997. Japanese clinical research enabler and providing site management office services. I'Rom Group has completed 1 acquisition, including CMAX. Its website iromgroup.co.jp draws about 14 thousand monthly visits. Its focus areas include Biopharma Outsourcing, CRO, Clinical Development and Functional Services.
Company details
IRom Group was founded in 1997 in Tokyo, Japan, within the clinical research sector. Site management office services are offered, including the establishment of medical malls across Japan for access to clinical trial sites. In 2007, Icros was created to deliver clinical research organization services. Capabilities in genetic drug development, cell treatment, and regenerative medicine were added through the 2014 acquisition of DNAVEC.
- Headquarters Tokyo, Japan
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website iromgroup.co.jp
- Investments & Acquisitions
Investments & Acquisitions by I'Rom Group
I'Rom Group has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include CMAX.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Early-phase clinical trials are conducted by CMAX laboratory in Adelaide. | cmax.com.au | Adelaide, Australia | 1993 | Oct 2016 | $4.91M |
Complete acquisition details for IRom Group
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of I'Rom Group
3 dated milestones of I'Rom Group across 19 years, from founding to its latest funding, stage changes and deals.
- Founded I'Rom Group is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires CMAX.
Web traffic of I'Rom Group
The website of I'Rom Group (iromgroup.co.jp) receives about 14.2K visits a month and ranks #1,401,786 among all websites worldwide, #1,815 in Biotechnology and Pharmaceuticals.
- Monthly visits14.2K
- Unique visitors6.8K
per month
- Global rank#1,401,786
among all websites
- Category rank#1,815
Health · Biotechnology and Pharmaceuticals
- Bounce rate36%
- Pages per visit3.4
- Average visit1 min 58 sec
- DevicesDesktop 45% · Mobile 55%
Websites whose visitors overlap most with I'Rom Group. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| yakuji.co.jp | 100% | #354,518 | View details | ||
1post.jp | 1post.jp | 60% | #458,845 | – | |
| discgenics.com | 60% | 2.8K | #6,148,199 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about I'rom Group
Complete news archive for IRom Group
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about I'Rom Group
I'Rom Group was founded in 1997.
I'Rom Group is headquartered in Tokyo, Japan. It is registered at Tokyo, Tokyo, Japan.
IRom Group was founded in 1997 in Tokyo, Japan, within the clinical research sector. Site management office services are offered, including the establishment of medical malls across Japan for access to clinical trial sites. In 2007, Icros was created to deliver clinical research organization services. Capabilities in genetic drug development, cell treatment, and regenerative medicine were added through the 2014 acquisition of DNAVEC.
I'Rom Group has made 1 acquisition, including CMAX.